Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CD69 | Q07108 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766231 | 1.00 | BTK (0.34) | BTKLATS1PDE2ACNR2F2R | |
| SCHEMBL26073300 | 1.00 | BTK (0.34) | BTKLATS1PDE2ACNR2F2R | |
| SCHEMBL26073296 | 0.86 | BTK (0.35) | BTKCNR2F2RGAAALDH1A1 | |
| SCHEMBL20532842 | 0.86 | TSHR (0.35) | BTKPDE2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20532841 | 0.86 | TSHR (0.35) | BTKPDE2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20683066 | 0.84 | BTK (0.39) | BTKCNR2GAAALDH1A1CD69 | |
| SCHEMBL29766427 | 0.84 | BTK (0.39) | BTKCNR2GAAALDH1A1CD69 | |
| SCHEMBL20683056 | 0.78 | BTK (0.36) | BTKCNR2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29766403 | 0.78 | BTK (0.36) | BTKCNR2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL20683042 | 0.76 | KMT2A (0.34) | BTKALDH1A1CYP3A4CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567453-A | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-110621670-B | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 比奥根MA公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| CN-110621670-A | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 比奥根MA公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885LATS1 566/4885PDE2A 795/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885LATS1 566/4885PDE2A 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.